Baseline demographics and ocular characteristics of patients with diabetes macular oedema including pre-outcomes and post-outcomes after treatment with anti-vascular endothelial growth factor therapy
| General characteristics | Diabetic macular oedema (n=31 eyes from 31 patients) |
| Age | |
| Median (min, max) | 61.0 (46, 72) |
| Gender | |
| Male | 20 (64.5%) |
| Female | 11 (35.5%) |
| Diabetes | |
| Type 1 | 7 (22.6%) |
| Type 2 | 24 (77.4%) |
| Retinopathy status | |
| Treated eye | |
| NPDR | 29 (93.5%) |
| PDR | 2 (6.5%) |
| Untreated eye | |
| NPDR | 31 (100%) |
| PDR | 0 (0%) |
| Duration of diabetes | |
| More than 10 years | 23 (74.2%) |
| 5–10 years | 7 (22.6%) |
| Less than 5 years | 1 (3.2%) |
| Baseline CSMT of eyes (median) (μm/range) | |
| Treated | 473 µm (range 321–566 µm) |
| Untreated | 347 µm (range 357–437 µm) |
| Post-treatment of CSMT of eyes (median) (μm/range) | |
| Treated | 301 µm (range 286–324 µm) |
| Untreated | 308 µm (range 259–317 µm) |
| Decrease in CSMT of eyes (μm) (median) (μm/range) | |
| Treated | −132 µm (range 93–156 µm) |
| Untreated | −18 µm (range 15–22 µm) |
CSMT, central subfield macular thickness; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy.